Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARLIGHT phase 3 trial of pabinafusp alfa versus idursulfase in mucopolysaccharidosis type II
MOH_2024-03-21_013312Phase 3Not yet recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Feb 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in mucopolysaccharidosis type 2 comparing Pabinafusp alfa arm with Idursulfase arm (2 arms). Primary endpoint: Primary endpoint not reported. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
pabinafusp alfaidursulfase
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on MOH_2024-03-21_013312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-21_013312.